ArriVent BioPharma Announces Program Update for FURVENT Trial
ArriVent BioPharma announced a program update from the Phase 3 FURVENT trial evaluating firmonertinib in first-line EGFR Exon 20 insertion mutant NSCLC.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.